Development of Bundibugyo Ebola Vaccine Gains Momentum Amid Outbreak
A potential vaccine targeting the Bundibugyo strain of Ebola has advanced in development, with funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and support from the World Health Organization (WHO). The candidate, based on a rVSV platform, aims to address a strain historically underprioritized due to lower mortality rates and limited commercial incentives.
Background on Bundibugyo Ebola
The Bundibugyo strain of Ebola, first identified in 2007 in Uganda, is genetically distinct from the more lethal Zaire strain. While it has caused smaller outbreaks, its lower fatality rate—estimated at 25-30% compared to Zaire’s 50-90%—has historically reduced urgency for vaccine development. However, recent outbreaks in the Democratic Republic of the Congo (DRC) have reignited interest, with the current crisis rivaling the scale of the 2013-2016 West African epidemic.
Challenges in Vaccine Development
Researchers like Dr. Scott Geisbert, a virologist at the University of Texas Medical Branch, have faced hurdles in advancing Bundibugyo-specific vaccines. A 2023 study published in *Nature Medicine* demonstrated that an rVSV-based vaccine protected monkeys from the strain, even when administered 20 minutes post-exposure. However, the lack of live virus samples for testing—due to logistical challenges in the DRC—has delayed further validation. “The 2% genetic difference from previous strains is a risk, but nothing’s foolproof,” Geisbert said, according to a 2024 interview with *WIRED*.
Funding and Regulatory Pathways
CEPI has allocated up to $3.2 million to support manufacturing preparations for Geisbert’s vaccine, marking a critical step toward human trials. The agency highlighted that prior regulatory experience with rVSV-based vaccines, such as the WHO-approved Ervebo for Zaire, could expedite approval. “Extensive safety data from Zaire strain vaccines could reduce development timelines,” said Rachael Bonawitz, CEPI’s filovirus disease program lead, in a 2024 email to *WIRED*.
Barriers to Commercialization
Despite progress, financial barriers persist. Courtney Woolsey, a lead author on the 2023 study, noted that “nobody really makes money off these vaccines,” citing limited market demand. The International AIDS Vaccine Initiative (IAVI), which will oversee production, focuses on diseases with low commercial incentives. “The baton has been handed off, and I just sit back and hope that it works,” Geisbert said, per *WIRED*.
Future Prospects and Global Preparedness
If successful, the vaccine could fill a critical gap in global Ebola preparedness. The WHO’s endorsement of the rVSV platform, following its success against the Sudan strain in a 2025 ring vaccination trial, underscores its potential. However, experts caution that the Bundibugyo strain’s genetic stability remains under scrutiny. “Even if it’s not used in this outbreak, clinical material could be available for the next,” Geisbert said, emphasizing the need for long-term investment.
Worth a look